Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David D Kim
Peter J Neumann

Showing results (101-110 of 436) with videos related to

Pageof 44
Sort By:
Journal of Managed Care & Specialty Pharmacy|October 31, 2019
Reflections on the ISPOR Special Task Force on U.S. Value Frameworks: Implications of a Health Economics Approach for Managed Care PharmacyLouis P Garrison, Peter J Neumann, Richard J Willke
Pharmacoeconomics|July 8, 2011
US FDA Modernization Act, section 114: uses, opportunities and implications for comparative effectiveness researchPeter J Neumann, Pei-Jung Lin, Tom E Hughes
Health Policy (Amsterdam, Netherlands)|December 16, 2014
Medicare's use of cost-effectiveness analysis for prevention (but not for treatment)James D Chambers, Michael J Cangelosi, Peter J Neumann
Journal of Managed Care Pharmacy : JMCP|November 6, 2008
Drug company advertising in medical journals about the health-economic advantages of their products for 2000-2006 versus 1990-1999Jennifer A Palmer, Alison R Timm, Peter J Neumann
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|August 19, 2020
Preparing the health-care system to pay for new Alzheimer's drugsPei-Jung Lin, Joshua T Cohen, Peter J Neumann
International Journal of Technology Assessment in Health Care|September 28, 2004
Cross-national comparison of technology assessment processesAnna García-Altés, Silvia Ondategui-Parra, Peter J Neumann
Health Affairs (Project Hope)|June 5, 2013
Medicare covers the majority of FDA-approved devices and Part B drugs, but restrictions and discrepancies remainJames D Chambers, Katherine E May, Peter J Neumann
The New England Journal of Medicine|February 15, 2008
Does preventive care save money? Health economics and the presidential candidatesJoshua T Cohen, Peter J Neumann, Milton C Weinstein
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 13, 2022
The History and Future of the "ISPOR Value Flower": Addressing Limitations of Conventional Cost-Effectiveness AnalysisPeter J Neumann, Louis P Garrison, Richard J Willke
Pediatric Neurology|October 23, 2016
Willingness to Pay for a Newborn Screening Test for Spinal Muscular AtrophyPei-Jung Lin, Wei-Shi Yeh, Peter J Neumann
Pageof 44

Showing results (101-110 of 436) with videos related to

Sort By:
Pageof 44
Journal of Managed Care & Specialty Pharmacy|October 31, 2019
Reflections on the ISPOR Special Task Force on U.S. Value Frameworks: Implications of a Health Economics Approach for Managed Care PharmacyLouis P Garrison, Peter J Neumann, Richard J Willke
Pharmacoeconomics|July 8, 2011
US FDA Modernization Act, section 114: uses, opportunities and implications for comparative effectiveness researchPeter J Neumann, Pei-Jung Lin, Tom E Hughes
Health Policy (Amsterdam, Netherlands)|December 16, 2014
Medicare's use of cost-effectiveness analysis for prevention (but not for treatment)James D Chambers, Michael J Cangelosi, Peter J Neumann
Journal of Managed Care Pharmacy : JMCP|November 6, 2008
Drug company advertising in medical journals about the health-economic advantages of their products for 2000-2006 versus 1990-1999Jennifer A Palmer, Alison R Timm, Peter J Neumann
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|August 19, 2020
Preparing the health-care system to pay for new Alzheimer's drugsPei-Jung Lin, Joshua T Cohen, Peter J Neumann
International Journal of Technology Assessment in Health Care|September 28, 2004
Cross-national comparison of technology assessment processesAnna García-Altés, Silvia Ondategui-Parra, Peter J Neumann
Health Affairs (Project Hope)|June 5, 2013
Medicare covers the majority of FDA-approved devices and Part B drugs, but restrictions and discrepancies remainJames D Chambers, Katherine E May, Peter J Neumann
The New England Journal of Medicine|February 15, 2008
Does preventive care save money? Health economics and the presidential candidatesJoshua T Cohen, Peter J Neumann, Milton C Weinstein
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 13, 2022
The History and Future of the "ISPOR Value Flower": Addressing Limitations of Conventional Cost-Effectiveness AnalysisPeter J Neumann, Louis P Garrison, Richard J Willke
Pediatric Neurology|October 23, 2016
Willingness to Pay for a Newborn Screening Test for Spinal Muscular AtrophyPei-Jung Lin, Wei-Shi Yeh, Peter J Neumann
Pageof 44